This bill, known as the STOP Nitazenes Act, directs the federal government to permanently classify nitazenes and related synthetic opioids as Schedule I controlled substances, placing them in the same legal category as heroin and fentanyl. The legislation specifically targets a broad range of chemical compounds, including etonitazene and other variants, by defining them as 2-benzylbenzimidazole opioids and requiring the Attorney General to publish a list of qualifying substances. Under the bill, any nitazene substance temporarily scheduled under emergency provisions would be made permanently scheduled upon enactment, ensuring long-term federal control. The law also mandates that the Attorney General issue implementing rules within one year, allowing for immediate interim enforcement while providing opportunities for public comment before final regulations are established.
This bill reauthorizes funding for the C.W. Bill Young Cell Transplantation Program, setting $31 million for fiscal year 2025 and $33 million annually for fiscal years 2027-2031. It also extends the deadline for the national cord blood inventory program from 2026 to 2031. The legislation directly affects stem cell research programs and cord blood banks by maintaining federal funding levels and prolonging the inventory program’s timeline. These provisions ensure continuity for existing research infrastructure and blood bank operations without introducing new policy changes.
This bill reauthorizes federal programs focused on preventing and responding to tick-borne diseases through 2026-2030, extending existing efforts beyond their previous expiration. It updates the National Strategy for Vector-Borne Diseases to emphasize identifying, reporting, preventing, and responding to these illnesses. The bill modifies two sections of the Public Health Service Act to continue funding for health departments working on vector-borne disease control. It directly affects public health programs and state/local health departments managing tick-borne disease prevention and response.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
This bill directs the Secretary of Defense to create the Senator Robert J. Dole Greatest Generation Education Program, which aims to increase public awareness of World War II history and its lessons. The program will operate by providing grants to state and local governments and nonprofit organizations to fund educational events that honor veterans, highlight the home front's contributions, and teach patriotism to young people. Recipients must use the funds for new initiatives rather than existing secondary school curricula, and the Department of Defense retains exclusive rights to the program's name and symbols.
This resolution honors the life and legacy of the late Senator Lindsey Olin Graham from South Carolina. It formally acknowledges his extensive career in the military, state government, and Congress, noting his service as a Senator and his roles as Chairman of the Judiciary and Budget committees. The Senate expresses its sorrow over his death and requests that this tribute be shared with the House of Representatives and Graham's family.
The TRUTH in Coverage Act of 2026 requires group health plans and health insurance issuers that cover gender-affirming procedures to also cover medical services aimed at treating the physical and psychological harms caused by those procedures. This mandate applies regardless of whether the original procedure was covered under the plan and ensures that follow-up care has the same cost-sharing rules and limitations as other standard medical benefits. The bill defines "sex-rejecting procedures" broadly to include hormone therapy, surgeries, and puberty blockers, while explicitly excluding treatments for intersex conditions, precocious puberty, and emergency care. Coverage for these restorative services would become effective for plan years starting on or after January 1, 2027.
The Ratepayer Protection Act establishes a new federal standard to protect utility customers from high electricity bills caused by large industrial users. It defines "large-load customers" as non-residential entities with a peak power demand of 100 megawatts or more that primarily use electricity for data centers and computing. Under this bill, these customers must pay for the full cost of any power plant, transmission line, or distribution upgrade needed to serve them, including costs incurred if the customer leaves the utility early. Additionally, utilities are required to obtain financial guarantees from these large customers before making such infrastructure investments. State regulators must review and implement these rules within two years, unless a state has already enacted similar protections.
This bill establishes a comprehensive sanctions framework targeting the Russian government and its affiliated entities in response to ongoing military actions. It authorizes the President to block assets, revoke visas, and prohibit financial transactions for Russian officials, military leaders, and foreign persons supporting Russia's defense industry or undermining Ukraine. The legislation also bans U.S. investments in Russian energy sectors, prohibits the purchase of Russian sovereign debt, and imposes high tariffs on Russian imports while restricting crude oil purchases by specific foreign nations. Additionally, the bill prevents Russian companies from listing on U.S. stock exchanges and includes mechanisms for terminating sanctions only if Russia signs a peace agreement accepted by Ukraine and ceases hostilities.
The Cancer Drug Parity Act of 2026 requires group health plans and insurance coverage to treat the cost-sharing for oral cancer medications no less favorably than that for intravenously administered cancer drugs. This rule applies to FDA-approved oral cancer treatments that a treating physician deems medically necessary and clinically appropriate, ensuring that deductibles, copayments, and coinsurance rates are not higher for oral options. The legislation also prohibits plans from making changes that would increase out-of-pocket costs or impose stricter limitations on oral cancer drugs compared to injected ones, while still allowing for standard utilization controls like prior authorization. Additionally, the bill mandates a Government Accountability Office study within two years to assess the impact of these changes on patient costs and access.
The POPCaP Act of 2026 establishes a precision oncology program within the Department of Veterans Affairs specifically for veterans diagnosed with prostate cancer. To deliver this care, the bill designates 21 existing VA medical centers across the country as provisional centers of excellence, requiring each to perform genetic sequencing, participate in clinical trials, and maintain specific staffing levels including oncologists and researchers. These centers will operate under a centralized leadership team that coordinates research activities, manages a national data registry, and ensures veterans have access to the latest biomarker-specific treatments. The legislation authorizes $15.5 million annually for fiscal years 2027 through 2029 to fund the program and mandates annual reports to Congress detailing patient outcomes and research progress.
The Essential Caregivers Act of 2026 requires nursing homes, long-term care hospitals, rehabilitation facilities, and intermediate care facilities to allow two chosen family members or friends to visit residents during times when regular visitation is suspended. These essential caregivers must agree to follow the facility's existing safety and infection control rules, which are no more restrictive than those applied to staff. While facilities can limit access for the first seven days of a suspension or deny entry if a caregiver shows symptoms of a serious infectious disease, they cannot block visits for end-of-life care. Additionally, the bill mandates that complaints about denied access to essential caregivers be investigated and resolved within three days.
